Slingshot members are tracking this event:

Agios Pharma (AGIO) to complete Phase 1 Study of AG-881 in patients with Hematologic Malignancies With an IDH1 or IDH2 Mutation in Q1 2018

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
High Medium Low
Impact on Stocks



Additional Information

Additional Relevant Details AG-881 is an orally available inhibitor of the mutated IDH1 and IDH2 proteins. In preclinical studies, it has shown to fully penetrate the blood-brain barrier, which has potential to support ongoing development efforts to provide treatment options to patients with glioma. It also represents a possible second-generation molecule for both AG-221 and AG-120 in IDH mutant tumors.
Clinical Data
  • Forty-eight percent of patients (n=25) had World Health Organization (WHO) classified Grade 2 tumors, 42% (n=22) had Grade 3 tumors, 8% (n=4) had Grade 4 tumors and 2% (n=1) was unknown.
  • Ninety-two percent of patients (n=48) had an IDH1 mutation and 6% (n=3) had an IDH2 mutation. One patient did not have a biopsy but was confirmed as IDH mutant positive due to 2-HG elevation by magnetic resonance spectroscopy (MRS).
  • The median age of these patients is 42.5 years (ranging from 16-73 years).
  • Patients received a median of two prior systemic therapies (ranging from one to six).
      -- Seventy-three percent of patients (n=38) had previously received temozolomide and 58% percent (n=30) had previously received radiotherapy.
  • Patients received daily doses of AG-881 ranging from 10 mg to 300 mg.
  • The median treatment duration was seven months (ranging from 0-27 months) for all glioma patients, 12 months (ranging from 1-27 months) for non-enhancing glioma and 3 months (ranging from 0- 27 months) for patients with enhancing disease.
  • http://investor.agio...
    Slingshot Insights Explained
    Related Projects Image
    • Don’t see a project related to the catalyst you care about?

    Related Keywords Phase 1 Study, Ag-881, Hematologic Malignancies, Idh1 Mutation, Idh2 Mutation, Acute Myeloid Leukemia, Myelodysplastic Syndrome, Open-label